Primary Progressive Multiple Sclerosis Clinical Trial
Official title:
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relationship to efficacy and safety To evaluate pharmacodynamics of SAR442168
Study duration will vary per participant in this event driven trial with a treatment duration of approximately 12 to 60 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02549703 -
Mitochondrial Dysfunction and Disease Progression
|
||
| Recruiting |
NCT02273635 -
Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05029609 -
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
|
Phase 1 | |
| Terminated |
NCT03283826 -
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05974839 -
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)
|
||
| Active, not recruiting |
NCT05974852 -
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
|
||
| Recruiting |
NCT04977622 -
Gray Matter Demyelination in Primary Progressive MS at 7T
|
||
| Recruiting |
NCT05893225 -
Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration
|
Phase 2 | |
| Completed |
NCT03094364 -
Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis
|
N/A | |
| Completed |
NCT02253264 -
A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
|
Phase 1 | |
| Recruiting |
NCT03691077 -
Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714
|
Phase 3 | |
| Completed |
NCT00950248 -
Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05232825 -
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
|
Phase 3 | |
| Recruiting |
NCT05229861 -
The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMS
|
N/A | |
| Completed |
NCT01077466 -
Natalizumab Treatment of Progressive Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT01854359 -
Idebenone for Primary Progressive Multiple Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT03493841 -
Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis
|
Phase 1 | |
| Active, not recruiting |
NCT03562975 -
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
|
||
| Completed |
NCT00731692 -
FTY720 in Patients With Primary Progressive Multiple Sclerosis
|
Phase 3 | |
| Recruiting |
NCT04943289 -
Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis
|
Phase 1 |